AI in Medical Information is transforming how pharmaceutical companies respond to healthcare professionals, patients, and caregivers. From intelligent scientific search to AI-generated responses, new technologies promise greater efficiency and lower operational costs.
But this raises an important question: Can AI replace medical information specialists, or will it simply change how they work?
The answer is more complicated than it first appears.
Medical information is not an ordinary customer service function. Every response must be scientifically accurate, medically appropriate, and consistent with regulatory and company requirements. A seemingly small error could have serious consequences.
To understand where AI fits, we need to examine what medical information teams do, which activities can be automated, and where human expertise remains essential.
1. What Do Medical Information Specialists Actually Do?
Medical information teams serve as a critical bridge between pharmaceutical companies and healthcare professionals, patients, and caregivers.
Their responsibilities often include:
- Responding to inquiries about drug efficacy, safety, dosing, and administration.
- Searching and interpreting scientific literature.
- Preparing and maintaining scientifically balanced, approved medical responses.
- Documenting inquiries and identifying potential adverse events or product quality complaints for appropriate reporting.
- Escalating complex questions to medical experts.
Unlike traditional customer support, medical information teams operate in a highly regulated environment.
For example, consider a physician asking whether a medication can be used in a patient population not covered by its approved labeling.
A medical information specialist may need to review clinical evidence, identify limitations, and provide a balanced response consistent with company policies and applicable regulations.
In the United States, the FDA provides guidance on communicating scientific information about unapproved uses of approved medical products. This illustrates why medical information responses require careful attention to scientific evidence, context, and regulatory expectations.
This requires more than retrieving information. It requires scientific judgment, context, and accountability.
2. Where Can AI Add Value Today?
The growing adoption of AI in Medical Information creates opportunities to automate repetitive tasks while preserving scientific oversight.
Intelligent Search and Information Retrieval
Traditional keyword searches may struggle when users phrase questions differently from the terminology used in scientific documents.
AI-powered semantic search can identify relevant information based on meaning rather than exact wording.
For example, a healthcare professional might ask:
“Can this medication be used in patients with poor kidney function?”
An AI-powered search system could identify relevant materials discussing renal impairment, even when the original question does not use that terminology.
The opportunity: Faster access to relevant scientific information, with citations and source verification.
AI-Assisted Response Drafting
Generative AI can help prepare initial responses using approved medical content.
Instead of starting from a blank page, specialists could review an AI-generated draft containing relevant information and references.
However, the distinction between drafting and approving a response is critical.
AI can generate a response. That does not mean the response is scientifically correct or authorized for distribution.
Inquiry Classification and Routing
AI can help classify incoming inquiries, identify topics, suggest appropriate response documents, and route complex questions to specialists.
For example, a routine product storage question might be directed to an approved response workflow, while a complex off-label inquiry could require additional medical review.
AI may also help flag potential safety information, but organizations must validate such workflows to avoid missed or incorrectly classified reports.
Medical Information Analytics
AI can analyze inquiry patterns to identify frequently asked questions, emerging information needs, and opportunities to improve approved content.
These insights could help Medical Affairs teams better understand healthcare professionals’ information needs and prioritize educational resources.
3. Can AI Actually Replace Medical Information Specialists?
The question of whether AI in Medical Information can replace specialists depends largely on the complexity and risk of each inquiry.
| Medical Information Activity | AI Potential | Human Involvement |
|---|---|---|
| Searching approved content | High | Verify relevance |
| Classifying inquiries | High | Review exceptions |
| Drafting standard responses | High | Review and approve as required |
| Summarizing literature | Moderate–high | Validate scientific interpretation |
| Handling complex off-label inquiries | Limited autonomy | Scientific judgment and oversight |
| Evaluating ambiguous safety information | Assistive | Qualified review and escalation |
These are qualitative assessments of technical potential, not validated automation rates.
Some routine activities may become highly automated. However, replacing an entire medical information specialist requires much more than automating individual tasks.
A specialist must recognize when available evidence is insufficient, when a question requires clarification, and when an inquiry presents a safety or compliance concern.
These are precisely the situations where AI systems may be least reliable.
4. The Biggest Challenge: Can We Trust AI-Generated Medical Responses?
Imagine asking an AI assistant to summarize three clinical studies.
It produces a polished response with scientific terminology, study results, and references.
Everything looks convincing.
But what if the AI incorrectly combines results from different studies? What if it invents a citation or overlooks an important limitation?
This is the challenge of AI hallucination.
In medical information, a confident but incorrect response can be more dangerous than an incomplete one.
Can AI Verify AI?
One proposed approach is to use a second AI system to evaluate the first system’s output.
Think of it as having one assistant write an answer and another assistant check the homework.
The second system might evaluate whether:
- Statements are supported by the cited sources.
- References actually exist.
- Numerical results match the underlying studies.
- The response includes unsupported medical claims.
- Required information is missing.
This approach can improve quality control, but it introduces another question:
What happens if both AI systems make the same mistake?
Two AI models agreeing does not necessarily mean their conclusion is correct.
A stronger validation strategy combines source-grounded generation, automated checks, independent testing, and human oversight.
The importance of AI validation is also recognized more broadly in pharmaceutical development. For example, the FDA has published draft guidance on establishing the credibility of AI models used to support regulatory decision-making for drugs and biological products.
Although this guidance addresses a different use case from routine medical information services, its emphasis on risk-based model assessment provides a useful perspective: AI outputs should be evaluated according to their intended use and the consequences of potential errors.
For pharmaceutical companies, AI verification should be treated as a risk-management process rather than a guarantee of accuracy.
5. What Does This Mean for Pharmaceutical Companies?
The business case for AI in Medical Information is compelling.
Companies may be able to reduce time spent searching for information, preparing routine responses, and performing administrative work.
But measuring success solely through headcount reduction would miss an important part of the equation.
A more meaningful evaluation would consider:
Operational efficiency: Does AI reduce response preparation time and improve productivity?
Scientific quality: Are responses accurate, balanced, complete, and supported by reliable sources?
Compliance: Can the organization demonstrate appropriate controls, traceability, documentation, and oversight?
Service quality: Are healthcare professionals receiving useful information quickly and consistently?
Total cost: Do efficiency gains outweigh implementation, validation, maintenance, monitoring, and review costs?
These measures are particularly important because AI systems require ongoing governance as models, approved content, products, and regulatory requirements change.
The need for responsible AI governance extends beyond medical information. The European Medicines Agency’s work on artificial intelligence addresses AI across the medicines lifecycle, reflecting the broader importance of appropriate oversight when AI is used in pharmaceutical activities.
For medical information leaders, this reinforces a practical principle: introducing AI is not simply a technology implementation. It also requires defined responsibilities, quality controls, and ongoing performance monitoring.
Measuring the return on investment of AI in Medical Information therefore requires evaluating efficiency alongside accuracy, compliance, and total operating costs.
6. BioIntel Perspective: From Replacing People to Redesigning Work
The most interesting opportunity may not be replacing medical information specialists.
It may be redesigning how medical information services operate.
Consider a future workflow:
- An inquiry enters the medical information system.
- AI identifies the topic and retrieves relevant approved materials.
- Generative AI prepares a source-grounded draft.
- Automated checks evaluate citations, factual consistency, and workflow requirements.
- A specialist reviews the response when required by its risk classification and company procedures.
- The system records the final response and relevant audit information.
For sufficiently standardized, low-risk inquiries, organizations may eventually validate more automated workflows.
For complex or high-risk inquiries, specialists would remain central to the process.
The result could be a medical information organization where professionals spend less time searching and formatting, and more time interpreting evidence, managing exceptions, and addressing complex scientific questions.
This represents a shift from task execution toward scientific oversight and decision-making.
7. What Should Pharma Leaders Do Next?
Before investing heavily in AI, pharmaceutical organizations should identify where automation creates measurable value without introducing unacceptable risks.
A practical starting point is a narrowly defined use case, such as retrieving approved response documents or drafting responses for specialist review.
Companies can then measure performance against existing processes, evaluate errors, and determine whether the workflow is suitable for broader deployment.
Rather than asking, “How many specialists can AI replace?” leaders should ask:
“Which activities can AI perform reliably, and how can we use that capability to improve the quality, speed, and sustainability of medical information services?”
That question leads to a more realistic AI strategy.
Conclusion: Replacement or Reinvention?
AI has significant potential to transform medical information operations, but the technology is not equivalent to a trained medical information specialist.
Retrieving scientific information, generating text, and making medically appropriate judgments are different capabilities.
Some activities may become increasingly automated. Others will continue to require human expertise, particularly where scientific uncertainty, patient safety, or regulatory obligations are involved.
The future of AI in Medical Information may therefore be less about replacing specialists and more about redefining their responsibilities.
The companies that succeed will not simply automate the most tasks. They will identify which tasks can be automated safely, demonstrate measurable value, and preserve accountability where it matters most.
📬 Join 100+ life sciences professionals getting monthly AI insights. No spam, just signal.